These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7214844)

  • 1. [Pattern of blood viscosimetric values, fibrinogen, and various glycoproteins in patients with obliterating sclerotic peripheral vascular disease treated with 3GS].
    Sarno A; Bruno S; Romano A; Catania A; la Bruzzo S; Francavilla G; Caimi G
    Clin Ter; 1980 Nov; 95(3):289-95. PubMed ID: 7214844
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations.
    Caramelli L; Mirchioni R; Carini A
    Riv Eur Sci Med Farmacol; 1988 Feb; 10(1):55-8. PubMed ID: 3079198
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinemias].
    Palmieri G; Perego M; Nazzari M; Casalini F
    Clin Ter; 1982 Jun; 101(6):603-14. PubMed ID: 7128029
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experience with sulodexide (Vessel Due F) in diabetics with ischemic disease of the lower extremities].
    Utratová J; Mayer J; Elbl L; Vorlícek J; Prásek J
    Vnitr Lek; 1993 Jun; 39(6):575-80. PubMed ID: 8212613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease.
    Castelluccio A; Bologna E
    Curr Med Res Opin; 1991; 12(5):325-31. PubMed ID: 2004545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Blood viscosimetric factors in cardiovascular pathology].
    Caimi G; Catania A; Romano A; Francavilla G; La Bruzzo S; Sarno A
    Minerva Cardioangiol; 1980 Sep; 28(9):611-20. PubMed ID: 7465068
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled defibrination in the treatment of peripheral vascular disease.
    Dormandy JA; Reid HL
    Angiology; 1978 Jan; 29(1):80-8. PubMed ID: 343654
    [No Abstract]   [Full Text] [Related]  

  • 8. [Study of blood viscosity and fibrinogen as a guide to the therapy of atherosclerotic peripheral arteriopathy].
    Savi I; Pola P
    Minerva Med; 1978 Dec; 69(63):4401-10. PubMed ID: 745806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial.
    Corsi C; Bocci L; Cipriani C; Gazzini A; Marrapodi E
    J Int Med Res; 1985; 13(1):40-7. PubMed ID: 3884410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic defibrinogenation in peripheral vascular disease.
    Ernst E
    Int Angiol; 1985; 4(3):373-7. PubMed ID: 3913715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol use, vascular disease, and lipid-lowering drugs.
    Kolovou GD; Salpea KD; Anagnostopoulou KK; Mikhailidis DP
    J Pharmacol Exp Ther; 2006 Jul; 318(1):1-7. PubMed ID: 16627749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sulodexide treatment approach in patients with atherosclerotic vascular disease with various localizations].
    Capone-Braga M; Tellini L; Boncompagni L; Bettoni M; Burali A; Bensi A
    Clin Ter; 1987 Jan; 120(1):25-31. PubMed ID: 2973852
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fibrinogen, a vascular risk factor].
    Caen JP; Soria J; Collet JP; Soria C
    Bull Acad Natl Med; 1993 Nov; 177(8):1433-41; discussion 1441-4. PubMed ID: 8193948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral vascular disease improved by clofibrate.
    Exp Med Surg; 1968; 26(4):277-9. PubMed ID: 5736504
    [No Abstract]   [Full Text] [Related]  

  • 15. [The clinical significance of blood viscosity in peripheral vascular disease].
    Adar R
    Harefuah; 1980 Apr; 98(7):317-9. PubMed ID: 7419119
    [No Abstract]   [Full Text] [Related]  

  • 16. Blood viscosity and red cell deformability in peripheral vascular disease.
    Cella G; De Haas H; Kakkar VV; Rampling MW
    Haematologica; 1979 Oct; 64(5):611-5. PubMed ID: 116921
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemorheology and tissue oxygenation in hypertensives with lipoidoproteinosis and peripheral occlusive arterial disease (POAD) treated with sulodexide and pravastatine and evaluated with laser assisted optical rotational red cell analyzer (LORCA) and transcutaneous oxymetry.
    Cicco G; Stingi GD; Vicenti P; Tarallo MS; Pirrelli A
    Minerva Cardioangiol; 1999 Oct; 47(10):351-9. PubMed ID: 10670256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The significance of sulodexide in the prevention of obliterative atherosclerotic arterial disease of the lower limbs].
    Martino R; Benini D
    Clin Ter; 1985 Mar; 112(5):429-37. PubMed ID: 4017468
    [No Abstract]   [Full Text] [Related]  

  • 19. Microhaemorheological properties of binifibrate. Part II: Preliminary open studies in patients with peripheral arteriopathies.
    Dalmau M; Monasterio J; Nogués R; Picó M; Freixes J; Bruseghini L; Diez S; Andreoli R
    Arzneimittelforschung; 1983; 33(6):858-61. PubMed ID: 6684440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of non-heparin glycosaminoglycans of natural origin.
    Bianchini P
    Semin Thromb Hemost; 1989 Oct; 15(4):365-9. PubMed ID: 2683090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.